DFTX Definium Therapeutics Inc.

The correlation between $DFTX and $XBI is near .8 or very strong at this point. so until big news we are just going to move with the index

$DFTX in all seriousness, though, this is actually pretty huge because I think the sell-off we’ve been seeing over the last week or so has been people derisking into another phase 3 trial results. The fact fact that the FDA gave them this breakthrough should be kind of looked at like a spoiler of what we’re gonna see later in this month

$DFTX they smoked it, the 50 blinding dose did exactly what it wanted to do. It’s perfect

$DFTX Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder https://www.businesswire.com/news/home/20260914329364/en/Definium-Therapeutics-Announces-Positive-Topline-Results-from-Phase-3-Panorama-Study-of-DT120-ODT-in-Generalized-Anxiety-Disorder • Study met primary and all key secondary efficacy endpoints • Participants receiving DT120 ODT 100 µg achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted change of 5.1 points from baseline at Week 12 (p<0.0001, Cohen’s d=0.64) • Pre-NDA meeting scheduled in 4Q 2026; NDA filing anticipated in 1H 2027

$DFTX RBC maintained it's outperform rating today on Definium Therapeutics(DFTX), with a $66 price target. Trial results are likely to support approval from the US Food and Drug Administration given DT120's robust efficacy data, well-powered studies, and the FDA's flexibility for neuropsychiatric drugs, according to the investment firm.

$DFTX dropping news tomorrow morning. Phase 3 data. Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 "announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD)."

$DFTX $CMPS $HELP this is the absolute most bullish time for this sector. We are witnessing a shake out before the parabolic climb!

$DFTX 6-9 months from now when these are 25-50% higher you'll be like why didn't I grow a pair..$CMPS

$DFTX Congrats to everyone who's been here since the "yacht week" "croatia" days. Just goes to show sometimes DCA'ng and holding / giving companies you believe in some time to cook can work in your favor.

$DFTX Couldn’t ask for a better start to Monday. $50 soon! Congrats to all the longs here. I remember first getting into MNMD back in the $2’s

$DFTX for the long term holders, we’ve been through a crazy ride. Crashes rallies, Freeman, lawsuits, uncertainty. Yet here we are 3/3 successful trials one more coming in 2027. 1 billion + in cash, potential partnership on the way. It’s been a wild ride.

$DFTX HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics(DFTX) with a Buy and maintains $70 price target.

$DFTX congrats here Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder "Study met primary and all key secondary efficacy endpoints; Panorama is the second positive Phase 3 trial for DT120 ODT in GAD and the third positive Phase 3 trial for DT120 ODT"

DFTX Stock Jumps Overnight As Investors Brace For Phase 3 Results From LSD-Based Anxiety Drug $DFTX $XBI https://stocktwits.com/news/equity/markets/dftx-stock-phase-3-results-lsd-based-anxiety-drug/cZtlNmbRBRG

$DFTX single pill for both GAD and MDD witch are usually co-morbidities, great efficacy; plus will be second psychedelic to be approved after Compass for MDD only = a winner in the making!

$DFTX I don't think we've even begun to see the fireworks, the run up had been huge and barely a soul beyond this board is talking about it. Sure there's some dry technical stuff on youtube but the youtubers with any significant influence are totally silent about anything other than AI. I believe that will change and when it does we will know the real boom is in motion.

$DFTX At present no competition in GAD. $HELP has HLP004 in development, and $LLY may switch one of the drugs they acquired to GAD, but you're looking at several years for both of those.

$DFTX Heidi Overton has been involved in efforts to advance executive actions that would fast-track regulatory reviews for psychedelic drugs. New fda appointee. Big news

$DFTX New BTD for MDD increases chances of filing NDA before results of second MDD trial. They could be filing for both GAD and MDD!

$DFTX - this psychedelic player seems quite logical as well on the pullback from $45 to $38 Broad phase 3's across GADD, MDD & PTSD with additional indications to follow, four late-stage trial wins to provide derisking First NDA filing 1H 27 + two more pivotal readouts